SEC Form 4 · accession 0001209191-16-096460
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Susan A. Knudson
Officer — Chief Financial Officer
Period of report
Feb 4, 2016
Accepted (ET)
Feb 8, 2016 · 5:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.9701 | Feb 4, 2016 | A | 45,000 | A | — | Feb 4, 2026 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1Option shares vest in 48 equal monthly installments beginning on March 4, 2016.